Through ongoing innovation in the GLP-1 space, Novo Nordisk has shifted the treatment paradigm in weight and health management. Now, the Company aims to continue raising the bar with a sharp focus on developing innovative treatment options, including new oral therapies. Join Dave Moore, Executive Vice President, US Operations of Novo Nordisk Inc., maker of semaglutide, for an intimate conversation on the company's plans to broaden access and offer new options to help manage weight and health, moving beyond current care models
